Retatrutide: Trial Evidence, Approval Status & What's Actually Legal

Retatrutide ('reta') is Eli Lilly's investigational triple-agonist for weight management — Phase 3 results are strong, but it is not approved anywhere yet. See what the trials show, why online 'reta' is grey market, and what the legitimate routes are. This page is informational and does not diagnose, prescribe, or recommend therapies.

Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.

Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.

Common contexts

Clinics may reference this peptide within broader wellness or longevity pathways.
Use this directory page to compare profile transparency and consultation options.

Safety information

This directory is informational and does not provide medical advice.
Always discuss suitability and risk profile directly with a licensed clinician.

Quick summary

Retatrutide (often shortened to 'reta') is Eli Lilly's investigational triple agonist — acting on GLP-1, GIP, and glucagon receptors — being developed for weight management.
Its Phase 3 TRIUMPH results are genuinely strong: the 12 mg dose produced average body-weight reductions of 20.8% (TRIUMPH-2) and 22.6% (TRIUMPH-3) at 80 weeks, versus roughly 3–4% on placebo.
It is not an approved medicine anywhere. Eli Lilly has said it plans to file for FDA approval in the first quarter of 2027, so there is currently no legal prescription route in the US or UK.
Because no approved product exists, 'retatrutide' sold online is a grey-market research chemical — and an unapproved medicine cannot be legally compounded either.
The only legitimate access today is through a clinical trial. Anyone told otherwise by a provider should treat that as a red flag.
This page is informational only — it does not diagnose, prescribe, recommend retatrutide, or provide dosing guidance.

Evidence at a glance

A scannable summary of what the current research and UK/US regulatory position actually show. Educational only — not medical advice, and no dosing guidance.

Evidence: Strong late-stage trial evidence: in Phase 3 TRIUMPH trials, the 12 mg dose produced average body-weight reductions of 20.8% (TRIUMPH-2) and 22.6% (TRIUMPH-3) at 80 weeks, versus roughly 3–4% on placebo. Still investigational — strong results are not approval.
Human data: Substantial and growing — large randomised Phase 3 trials have reported topline results. Long-term and real-world safety data are still accumulating.
UK regulatory status: Not a licensed UK medicine — no MHRA marketing authorisation exists. The only legitimate access is through a clinical trial; anything sold online as 'retatrutide' is an unlicensed grey-market product.
US regulatory status: Not FDA-approved. Eli Lilly has stated it plans to file for approval in the first quarter of 2027. As an unapproved medicine it also cannot be legally compounded — vials sold online are unregulated research chemicals.
Anti-doping (sport): GLP-1-class weight-management medicines are not currently named on the WADA prohibited list, but tested athletes should always check the current list before using any investigational substance.

Last reviewed 13 August 2026. Regulatory status can change — always confirm the current position with a qualified clinician.

Claim vs evidence

Common marketing and internet claims about Retatrutide, set against what the research actually shows. Educational only — not medical advice.

Claim	Human evidence	What the evidence shows
“The strongest weight-loss drug ever — beats tirzepatide”	Phase 3 data	The trial results are genuinely strong (20–23% average loss at 80 weeks), but cross-trial comparisons are unreliable and no head-to-head trial against tirzepatide has been published. 'Strongest ever' is marketing, not a trial conclusion.
“You can buy real retatrutide online now”	No legal route	No approved retatrutide product exists anywhere, so nothing sold online comes from a regulated supply chain. Grey-market vials have no verified identity, dose, or purity, and counterfeits are common in this category.
“Clinics can offer it as a compounded medicine”	Not permitted	Compounding is a regulated route built around approved medicines — an unapproved investigational drug cannot be legally compounded. A provider offering 'compounded retatrutide' today is operating outside the regulated pathway.
“It's basically the next Mounjaro, so it's safe”	Not established	Its safety profile is still being characterised in ongoing trials. Related medicines being approved does not make an investigational one safe — and grey-market use lacks the screening and monitoring trial participants receive.

Clear intro

Retatrutide pages attract enormous search interest off the back of its trial results. The honest position — which strong clinics share — is that the data is genuinely promising, approval has not happened yet, and the grey market that has grown around the name is unregulated and risky.

Who this is for

This page is for people who have seen retatrutide's trial headlines and want to know what is actually available, legal, and supervised today — and for anyone weighing grey-market 'reta' against a properly prescribed alternative.

What to ask before choosing a clinic

Retatrutide isn't approved yet — what approved options exist for my goal, and how do they compare?
Would I be a candidate for a retatrutide clinical trial, and where would I find one?
How do you handle patients who arrive already using grey-market products?

Pricing and red flags

No approved product means no legitimate pricing. Compare supervised programmes using approved medicines instead, and treat any 'retatrutide price list' as a grey-market warning sign.

Any provider selling or 'prescribing' retatrutide before approval — no legal route exists.
'Compounded retatrutide' offers — an unapproved medicine cannot be legally compounded.
Marketing that quotes trial percentages as guaranteed personal results.

What is Retatrutide?

Retatrutide is an investigational injectable medicine developed by Eli Lilly that acts on three receptors at once — GLP-1, GIP, and glucagon — which is why it is often called a 'triple agonist' or 'triple-G'. It sits in the same broad family as semaglutide (a GLP-1 agonist) and tirzepatide (a dual GLP-1/GIP agonist), but adds glucagon-receptor activity. In Phase 3 trials it has produced some of the largest average weight reductions reported for any medicine in this class. Crucially, it remains investigational: it has no FDA approval, no MHRA licence, and no approved product anywhere in the world, with Lilly's US filing planned for early 2027.

How it works

Like other incretin-based medicines, retatrutide influences appetite, satiety, and metabolic signalling — with the added glucagon-receptor activity thought to increase energy expenditure. The headline trial numbers are impressive, but they come from monitored trial settings with structured titration, side-effect management, and exclusion criteria. They say little about unsupervised use of unverified grey-market vials, which is where most non-trial 'retatrutide' currently comes from.

Typical use cases

Weight-management research contexts — it is being developed for obesity and related metabolic conditions, with trial results driving intense public interest.
Comparisons with approved options, since most people searching for retatrutide are really weighing it against semaglutide or tirzepatide, which can be legally prescribed today.
Clinical-trial participation — the only legitimate way to access retatrutide right now.

Cost overview

There is no legitimate consumer price for retatrutide because no approved product exists. Anything on sale today is grey market. If pricing matters, the meaningful comparison is between properly supervised programmes using approved medicines in the same class. See the peptide therapy cost guide.

What to expect from clinics

A credible clinic should tell you plainly that retatrutide is not yet an approved medicine and cannot be legally prescribed or compounded.
Expect a discussion of approved alternatives with proper supervision rather than an offer of 'early access'.
Be cautious of any provider selling 'retatrutide' today — no regulated supply chain for it exists.

Safety considerations

Retatrutide's safety profile is still being characterised in ongoing trials, and by definition an investigational medicine has incomplete long-term safety data. Trial participants are screened, titrated, and monitored in ways grey-market users are not, and unregulated vials carry the added risks of unknown identity, dose, and purity. This page does not recommend retatrutide and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.

Frequently asked questions about Retatrutide

Is retatrutide FDA-approved or available on the NHS?

No. Retatrutide is investigational — it has no FDA approval and no MHRA licence. Eli Lilly has said it plans to file for FDA approval in the first quarter of 2027. Until approval, there is no legal prescription route in the US or UK.

Can I legally buy retatrutide anywhere?

No. Because no approved product exists, there is no regulated retail or pharmacy supply. Products sold online as 'retatrutide' or 'reta' are grey-market research chemicals with no verified identity, dose, or purity. The only legitimate access is through a clinical trial.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide targets GLP-1, tirzepatide targets GLP-1 and GIP, and retatrutide targets GLP-1, GIP, and glucagon — hence 'triple agonist'. The practical difference today is regulatory: semaglutide and tirzepatide are approved, prescribable medicines; retatrutide is not.

What did the Phase 3 trials actually show?

In topline results from the TRIUMPH programme, the 12 mg dose produced average body-weight reductions of 20.8% (TRIUMPH-2) and 22.6% (TRIUMPH-3) at 80 weeks, versus roughly 3–4% on placebo. These are trial averages under medical supervision, not guaranteed individual results.

When will retatrutide be available?

Eli Lilly has stated it plans to submit its FDA application in the first quarter of 2027, which means any approval — and availability — would follow later, subject to regulatory review. Timelines can move; treat any provider claiming early access today with caution.

Does Peptide Clinic Finder sell or recommend retatrutide?

No. Peptide Clinic Finder is an informational directory. We do not sell retatrutide, provide medical advice, or recommend its use — we explain its real regulatory status so you can make informed decisions with a licensed clinician.

Related comparisons: Retatrutide vs Tirzepatide.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Compare Providers Get Matched Browse city clinics

Related Retatrutide pages

Move from peptide research into clinic comparisons, guides, and matching.

LiveNow Longevity Retatrutide vs Tirzepatide Menon Health Extend Medical 360 MD Austin Anderson Longevity Clinic Aspire Rejuvenation Clinic

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering Retatrutide

No clinics are currently tagged with this peptide. Explore related goals, conditions, and comparisons below.

Explore clinics by city

Miami peptide clinics Los Angeles peptide clinics New York peptide clinics All US locations

What to do next

Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.

Compare Providers Get Matched Miami clinics Los Angeles clinics New York clinics